Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study

Carole Burillon,1 Frederic Chiambaretta,2 Pierre-Jean Pisella3 1Ophthalmology Department, University Hospital HCL, GH Edouard Herriot, Lyon, France; 2Ophthalmology Department, Clermont-Ferrand University Hospital, Hôpital Gabriel Montpied, Clermont Ferrand, France; 3Ophthalmology Departme...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Burillon C, Chiambaretta F, Pisella PJ
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2018
Materias:	Dry eye disease hyaluronic sodium glycyrrhizin inflammation ocular lesions Ophthalmology RE1-994
Acceso en línea:	https://doaj.org/article/a082f12deec74996bf7ba3f895f0df5a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a082f12deec74996bf7ba3f895f0df5a
record_format	dspace
spelling	oai:doaj.org-article:a082f12deec74996bf7ba3f895f0df5a2021-12-02T05:54:04ZEfficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study1177-5483https://doaj.org/article/a082f12deec74996bf7ba3f895f0df5a2018-12-01T00:00:00Zhttps://www.dovepress.com/efficacy-and-safety-of-glycyrrhizin-25-eye-drops-in-the-treatment-of-m-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Carole Burillon,1 Frederic Chiambaretta,2 Pierre-Jean Pisella3 1Ophthalmology Department, University Hospital HCL, GH Edouard Herriot, Lyon, France; 2Ophthalmology Department, Clermont-Ferrand University Hospital, Hôpital Gabriel Montpied, Clermont Ferrand, France; 3Ophthalmology Department, Paris Nord Val-de-Seine University Hospitals, Hôpital Bretonneau, Tours, France Background: Dry eye disease (DED) is characterized by a loss of homeostasis of the tear film. It goes along with ocular symptoms, in which ocular surface inflammation and damage play etiological roles. High-mobility group box 1 protein (HMGB1) is a pro-inflammatory protein found in the tear fluid during conjunctivitis, blepharitis and DED. Glycyrrhizin binds to HMGB1, inhibiting cytokine activities, thus potentially improving DED.Aim: To assess the efficacy and tolerance of glycyrrhizin in moderate DED.Methods: Multicenter, open-label, prospective, nonrandomized clinical pilot study of glycyrrhizin 2.5% eye drops twice daily over 28 days in adult patients with moderate DED using standard evaluation parameters.Results: The overall mean age of the 37 patients included was 59.6±19.0 years, 70.3% of the patients were female and 77.0% of the patients had an Oxford score of II. After 28 days, 60.8% of the patients had an Oxford score of 0 or I; a significant mean improvement in the score of 0.97±0.86 (P<0.001) from 2.20±0.44 at day 1 to 1.23±0.88 at day 28 was observed. Tear break-up time and Schirmer scores had significantly improved while the number of patient-reported symptoms had significantly decreased (all P≤0.010). A large majority of patients still had a few spots on their naso-bulbar conjunctiva (86.1%), temporal-bulbar conjunctiva (81.4%) and cornea (84.7%). The investigators considered that DED had improved in 71.6% of the patients. Patients appreciated the eye drops for their efficacy and good tolerance profile, leading to a decreased use of artificial tears. No changes in intraocular pressure and visual acuity were observed; glycyrrhizin 2.5% eye drops were safe, with only one patient reporting a moderate, transient treatment-related contact allergy leading to the withdrawal of the patient. Overall, two patients reported three adverse events, two (moderate contact allergy in both eyes) were related to the eye drops and experienced by the same patient; treatment was stopped; the third event was not treatment-related.Conclusion: In this pilot study, glycyrrhizin 2.5% eye drops were well tolerated and provide a good clinical benefit to patients with moderate DED after 28 days of continued daily use. Keywords: dry eye disease, hyaluronic sodium, glycyrrhizin, inflammation, ocular lesionsBurillon CChiambaretta FPisella PJDove Medical PressarticleDry eye diseasehyaluronic sodiumglycyrrhizininflammationocular lesionsOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 12, Pp 2629-2636 (2018)
institution	DOAJ
collection	DOAJ
language	EN
topic	Dry eye disease hyaluronic sodium glycyrrhizin inflammation ocular lesions Ophthalmology RE1-994
spellingShingle	Dry eye disease hyaluronic sodium glycyrrhizin inflammation ocular lesions Ophthalmology RE1-994 Burillon C Chiambaretta F Pisella PJ Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
description	Carole Burillon,1 Frederic Chiambaretta,2 Pierre-Jean Pisella3 1Ophthalmology Department, University Hospital HCL, GH Edouard Herriot, Lyon, France; 2Ophthalmology Department, Clermont-Ferrand University Hospital, Hôpital Gabriel Montpied, Clermont Ferrand, France; 3Ophthalmology Department, Paris Nord Val-de-Seine University Hospitals, Hôpital Bretonneau, Tours, France Background: Dry eye disease (DED) is characterized by a loss of homeostasis of the tear film. It goes along with ocular symptoms, in which ocular surface inflammation and damage play etiological roles. High-mobility group box 1 protein (HMGB1) is a pro-inflammatory protein found in the tear fluid during conjunctivitis, blepharitis and DED. Glycyrrhizin binds to HMGB1, inhibiting cytokine activities, thus potentially improving DED.Aim: To assess the efficacy and tolerance of glycyrrhizin in moderate DED.Methods: Multicenter, open-label, prospective, nonrandomized clinical pilot study of glycyrrhizin 2.5% eye drops twice daily over 28 days in adult patients with moderate DED using standard evaluation parameters.Results: The overall mean age of the 37 patients included was 59.6±19.0 years, 70.3% of the patients were female and 77.0% of the patients had an Oxford score of II. After 28 days, 60.8% of the patients had an Oxford score of 0 or I; a significant mean improvement in the score of 0.97±0.86 (P<0.001) from 2.20±0.44 at day 1 to 1.23±0.88 at day 28 was observed. Tear break-up time and Schirmer scores had significantly improved while the number of patient-reported symptoms had significantly decreased (all P≤0.010). A large majority of patients still had a few spots on their naso-bulbar conjunctiva (86.1%), temporal-bulbar conjunctiva (81.4%) and cornea (84.7%). The investigators considered that DED had improved in 71.6% of the patients. Patients appreciated the eye drops for their efficacy and good tolerance profile, leading to a decreased use of artificial tears. No changes in intraocular pressure and visual acuity were observed; glycyrrhizin 2.5% eye drops were safe, with only one patient reporting a moderate, transient treatment-related contact allergy leading to the withdrawal of the patient. Overall, two patients reported three adverse events, two (moderate contact allergy in both eyes) were related to the eye drops and experienced by the same patient; treatment was stopped; the third event was not treatment-related.Conclusion: In this pilot study, glycyrrhizin 2.5% eye drops were well tolerated and provide a good clinical benefit to patients with moderate DED after 28 days of continued daily use. Keywords: dry eye disease, hyaluronic sodium, glycyrrhizin, inflammation, ocular lesions
format	article
author	Burillon C Chiambaretta F Pisella PJ
author_facet	Burillon C Chiambaretta F Pisella PJ
author_sort	Burillon C
title	Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
title_short	Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
title_full	Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
title_fullStr	Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
title_full_unstemmed	Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
title_sort	efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study
publisher	Dove Medical Press
publishDate	2018
url	https://doaj.org/article/a082f12deec74996bf7ba3f895f0df5a
work_keys_str_mv	AT burillonc efficacyandsafetyofglycyrrhizin25eyedropsinthetreatmentofmoderatedryeyediseaseresultsfromaprospectiveopenlabelpilotstudy AT chiambarettaf efficacyandsafetyofglycyrrhizin25eyedropsinthetreatmentofmoderatedryeyediseaseresultsfromaprospectiveopenlabelpilotstudy AT pisellapj efficacyandsafetyofglycyrrhizin25eyedropsinthetreatmentofmoderatedryeyediseaseresultsfromaprospectiveopenlabelpilotstudy
_version_	1718400187073822720

Efficacy and safety of glycyrrhizin 2.5% eye drops in the treatment of moderate dry eye disease: results from a prospective, open-label pilot study

Ejemplares similares